RenovoRx

A rendering of the RenovoGem platform. [Image courtesy of RenovoRx]RenovoRx announced today that it closed a private placement bringing in gross proceeds of approximately $6.1 million.

Los Altos, California-based RenovoRx develops precision oncology therapies based on a local drug delivery platform. Closing this funding round extends the company’s cash runway as it conducts its pivotal TIGer-PaC Phase III clinical trial. It expects the funds to aid operations through 2024.

TIGer-PaC uses RenovoRx’s proprietary TAMP therapy platform to evaluate its first product candidate, the RenovoGem. RenovoGem, a novel oncology drug-device combination, is designed to treat locally advanced pancreatic cancer (LAPC). The study compares TAMP treatment to the current standard of care, systemic intravenous chemotherapy.

Get the full story at our sister site, Drug Delivery Business News.

A rendering of the RenovoGem platform. [Image courtesy of RenovoRx]RenovoRx (Nasdaq:RNXT) today announced promising interim data for its RenovoGem drug-device combination for treating pancreatic cancer.

The Tiger-Pac clinical trial investigates RenovoGem as a potential treatment option in locally advanced pancreatic cancer (LAPC). Interim data from the Phase III open-label study suggests a six-month potential improvement in median overall survival with RenovoGem.

RenovoGem utilizes the RenovoRx proprietary RenovoTAMP therapy platform. It provides targeted intra-arterial delivery of FDA-approved chemotherapy, known as gemcitabine. This treats LAPC following stereotactic body radiation therapy (SBRT). The pressure-mediated delivery technology delivers the therapy locally, across the arterial wall to bathe tumor tissue in chemotherapy.

Get the full story at our sister site, Drug Delivery Business News.

RenovoRx today said it received FDA 510(k) clearance for its RenovoCath delivery system.

Los Altos, California-based RenovoRx designed the system as the device component for its RenovoGem and is a drug/device combination used in the company’s RenovoTAMP trans-arterial micro-perfusion therapy. The system is a dual-balloon infusion catheter that delivers chemotherapy directly to tumors through the arteries.

Get the full story on our sister site, Medical Tubing + Extrusion.